Holliday cashes in on Glaxo's misery
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.While Glaxo Wellcome is facing sleepless nights following the patent expiry of Zantac, its blockbuster ulcer drug, in the US, Holliday Chemicals, which makes the generic version of Zantac, is cashing in. Shares in the company soared 15 per cent to 176.5p yesterday after the company announced a 64 per cent jump in profits to pounds 13m, boosted by a pounds 4m contribution from supplying generic Zantac, called ranitidine, into the US market.
Mark Robbins, joint chief executive, said generic companies in the US had been buying in large quantities of ranitidine in readiness for the Glaxo patent expiry in July. Holliday is one of the biggest suppliers of the drug into the US, supplying most of the generic players, including Novopharm, Geneva and Genpharm. "Ranitidine is definitely a boost to us. It is a huge market in the US," he said.
Mr Robbins denied that acourt case brought by Glaxo, which claims Holliday's Spanish subsidiary, Uquifa, is infringing its Zantac patent and could threaten to halt the supply of ranitidine into the US, was an issue.
Mr Robbins said a complex litigation process which resulted in only one generic company, Novopharm, having the right to sell ranitidine until the end of August was benefiting the group, though the outlook depended on how many generics entered the market: "The fewer players there are, the better for us. Generic drugs are price-sensitive. If there are 15 players in the market, the price could fall by 90 per cent."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments